Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors
Introduction:
Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board
Spruce Biosciences, a late-stage biopharmaceutical company focusing on rare endocrine disorders, has announced the appointment of Percival Barretto-Ko to its Board of Directors. Barretto-Ko, a seasoned life sciences industry executive, brings over two decades of commercial and biopharmaceutical expertise to the company. This article highlights the details of the appointment and acknowledges the contributions of the departing board member, Dina Chaya, Ph.D.
Percival Barretto-Ko joins Spruce Biosciences’ Board of Directors
Spruce Biosciences welcomes Percival Barretto-Ko as a new member of its Board of Directors. With a distinguished career spanning more than 20 years in the life sciences industry, Barretto-Ko brings extensive commercial and biopharmaceutical experience to the company. His appointment is expected to strengthen Spruce’s expertise in rare endocrine disorders.
Departure of Dina Chaya from the Board of Directors
The announcement of Percival Barretto-Ko’s appointment also includes the departure of Dina Chaya, Ph.D., from Spruce Biosciences’ Board of Directors. Chaya’s contributions over the past three years have been instrumental in advancing Spruce’s pipeline, from early proof-of-concept to late-stage clinical development. The company expresses gratitude for Chaya’s significant role in guiding their progress.
Percival Barretto-Ko’s Impression and Commitment to Spruce Biosciences
Percival Barretto-Ko, upon joining Spruce Biosciences, expresses his admiration for the progress the company has made in advancing tildacerfont, a potential treatment for rare endocrine disorders. He acknowledges the potential of tildacerfont to transform the treatment landscape for patients with congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Barretto-Ko emphasizes his dedication to leveraging his global experience to support the development and commercialization of groundbreaking therapies for rare endocrine disorders.
Spruce Biosciences’ Focus on Rare Endocrine Disorders
Spruce Biosciences is a late-stage biopharmaceutical company dedicated to addressing significant unmet medical needs in the field of rare endocrine disorders. With a particular focus on conditions such as congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS), Spruce aims to develop and commercialize innovative therapies that can make a meaningful difference in the lives of patients.
Tildacerfont: A Potential Breakthrough in Rare Endocrine Disorder Treatment
Spruce Biosciences’ lead product candidate, tildacerfont, holds great promise for patients with rare endocrine disorders. As a potential first non-steroidal therapy for classic congenital adrenal hyperplasia (CAH) and primary adrenal androgen excess in polycystic ovary syndrome (PCOS), tildacerfont has the potential to revolutionize treatment approaches and significantly improve patient outcomes.
Spruce Biosciences’ Participation in the Jefferies Healthcare Conference
In addition to the recent appointment, Spruce Biosciences is set to participate in the Jefferies Healthcare Conference. Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences, will present at the conference on June 9, 2023. This provides an opportunity for the company to showcase its advancements and potential breakthrough therapies for rare endocrine disorders.
Conclusion:
Spruce Biosciences’ appointment of Percival Barretto-Ko to its Board of Directors reflects the company’s commitment to advancing innovative therapies for rare endocrine disorders. Barretto-Ko’s extensive commercial and biopharmaceutical expertise is expected to contribute significantly to the potential commercialization of tildacerfont, Spruce’s lead product candidate. With the addition of Barretto-Ko and recognition of Dina Chaya’s contributions, Spruce Biosciences continues to strengthen its position in the field of rare endocrine disorders, bringing hope to patients in need of effective treatments. The company’s focus on rare endocrine disorders and the potential breakthrough of tildacerfont highlight its dedication to addressing significant unmet medical needs in this area. Furthermore, their participation in the Jefferies Healthcare Conference provides a platform to showcase their progress and foster collaboration within the healthcare industry.
